Details for Patent: 8,952,018

Which drugs does patent 8,952,018 protect, and when does it expire?

Patent 8,952,018 protects TAFINLAR and MEKINIST and is included in two NDAs.

Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-six patent family members in thirty-four countries.

Summary for Patent: 8,952,018

Title:	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Abstract:	A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
Inventor(s):	Melissa Dumble, Rakesh Kumar, Sylvie Laquerre, Peter Lebowitz
Assignee:	Novartis Pharma AG , Novartis Pharmaceuticals Corp
Application Number:	US14/197,421
Patent Claim Types: see list of patent claims	Use;

US Patent 8,952,018: Scope, Claims, Expiration, Orange Book Status, and Patent Landscape for Dabrafenib-Trametinib

US Patent 8,952,018 protects the use of dabrafenib, including its dimethyl sulfoxide solvate, together with trametinib, including its methanesulfonate salt, to treat non-small cell lung cancer. The most commercially important limitation is claim 4, which covers BRAF V600E-mutant non-small cell lung cancer. The patent is directed to combination treatment, not dabrafenib or trametinib monotherapy.

The patent is associated with the Tafinlar-Mekinist combination marketed by Novartis. Its principal commercial value is the protection of the approved BRAF V600E-positive metastatic NSCLC indication and related combination use.

What drugs and therapeutic combination does US Patent 8,952,018 cover?

The compounds identified by formula I and formula II correspond to dabrafenib and trametinib, respectively.

Patent reference	Drug	Common product	Relevant pharmaceutical form
Formula I	Dabrafenib	Tafinlar	Dabrafenib, including the dimethyl sulfoxide solvate
Formula II	Trametinib	Mekinist	Trametinib, including the methanesulfonate salt
Combination	Dabrafenib plus trametinib	Tafinlar plus Mekinist	Oral combination therapy

Dabrafenib is a selective BRAF kinase inhibitor. Trametinib is a MEK1/2 inhibitor. The combination suppresses signaling downstream of mutant BRAF and was developed for tumors driven by activating BRAF mutations.

The commercial regimen for BRAF V600E-mutant metastatic NSCLC is dabrafenib 150 mg orally twice daily combined with trametinib 2 mg orally once daily. The FDA approved the combination for BRAF V600E-mutant metastatic NSCLC in 2018 under an accelerated approval pathway based on response-rate data and duration of response [2].

What do the claims of US Patent 8,952,018 cover?

Claim 1: Broad combination-treatment claim

Claim 1 covers:

1. A human patient;
2. Non-small cell lung cancer;
3. Administration of a therapeutically effective amount of dabrafenib or an accepted salt or solvate; and
4. Administration of a therapeutically effective amount of trametinib or an accepted salt.

The claim does not expressly require:

• BRAF V600E mutation status;
• metastatic disease;
• a particular dose;
• a specific dosing schedule;
• simultaneous administration;
• co-formulation in a single dosage form;
• prior failure of another therapy;
• a particular line of treatment; or
• a particular route of administration, although the approved products are oral.

The use of the term “comprises” generally makes the claim open-ended. A treatment regimen could therefore include additional anticancer agents, supportive medicines, radiation, surgery or other interventions, subject to ordinary claim-construction principles.

Claim 1 is commercially broader than claim 4 because it covers NSCLC without expressly limiting the disease to BRAF V600E-mutant tumors. Its practical enforceability would depend on whether the accused treatment falls within the formula definitions and whether the patent’s written description and enablement support the full disease scope.

Claim 2: Dabrafenib dimethyl sulfoxide solvate

Claim 2 narrows claim 1 by requiring compound I in the form of the dimethyl sulfoxide solvate. This is the form commonly associated with dabrafenib mesylate in the marketed Tafinlar product, although the claim language supplied refers specifically to the solvate form.

This claim is narrower than claim 1 but may be more closely aligned with the commercial pharmaceutical form. A generic product using the same active ingredient and the same claimed solid form would face a direct infringement risk if it is marketed for the claimed NSCLC use.

Claim 3: Trametinib methanesulfonate salt

Claim 3 narrows claim 1 by requiring compound II in the methanesulfonate salt form. The claim targets the marketed salt form of trametinib.

A product using a different pharmaceutically acceptable salt could avoid literal infringement of claim 3, but it could remain exposed under claim 1 if the alternative form falls within the broader claim language. The availability of a non-infringing alternative would also depend on the precise definitions and prosecution history.

Claim 4: BRAF V600E-mutant NSCLC

Claim 4 limits the disease to BRAF V600E-mutant NSCLC. This is the most direct claim to the FDA-approved Tafinlar-Mekinist NSCLC indication.

The claim requires:

• NSCLC;
• a BRAF V600E mutation; and
• combination administration of dabrafenib and trametinib.

It does not appear, from the supplied language, to require a particular stage, metastatic status, prior treatment history or dose. The claim therefore has strong relevance to labeled use but may not reach treatment of NSCLC driven by other BRAF mutations, non-BRAF alterations or tumors in other histologies.

Claim 5: Parallel combination claim

Claim 5 repeats the core combination concept but uses narrower salt language for the compounds. Based on the supplied text, claim 5 requires:

• compound I or a pharmaceutically acceptable salt;
• compound II or a pharmaceutically acceptable salt; and
• treatment of NSCLC.

Unlike claim 1 as supplied, claim 5 does not expressly include solvates for compound I. This creates a potentially meaningful distinction for a product using a solvate rather than only a salt. The difference would be assessed against the patent specification, prosecution history and the chemical identity of the marketed dosage form.

How broad is the infringement scope of US 8,952,018?

The patent has four principal infringement pathways.

Potential accused conduct	Claim exposure
Marketing dabrafenib plus trametinib for NSCLC	High under claim 1 and claim 5
Marketing the combination specifically for BRAF V600E-mutant NSCLC	High under claim 4
Using dabrafenib DMSO solvate with trametinib methanesulfonate	Potential exposure under claims 1-4
Using either drug alone	Generally outside the supplied claims
Using the combination for melanoma only	Outside the express NSCLC limitation
Using dabrafenib with a different MEK inhibitor	Outside the claims if formula II is trametinib
Using trametinib with a different BRAF inhibitor	Outside the claims if formula I is dabrafenib
Treating non-NSCLC tumors	Outside the express disease limitation

The patent does not appear to claim the active ingredients as chemical compounds. It is a method-of-treatment patent. Its value therefore depends on the combination being used or promoted for NSCLC, rather than simply being manufactured or dispensed for an unrelated indication.

A generic manufacturer could face different risks depending on its proposed labeling. A skinny label excluding NSCLC may reduce inducement exposure, but it would not eliminate all risk if the product is marketed with materials, instructions or commercial conduct that encourage the patented combination use.

What is the patent expiration date for US 8,952,018?

US Patent 8,952,018 was issued on February 10, 2015. Public patent-family records identify a 2009 priority date for the underlying combination-therapy disclosure, producing an expected U.S. patent-term expiration in 2030, subject to any patent-term adjustment, terminal disclaimer or other term calculation recorded by the USPTO [1].

Event	Date
Earliest reported priority	August 4, 2009
U.S. filing and continuation history	Patent-family dependent
U.S. publication	2013
Patent grant	February 10, 2015
Expected base expiration	August 4, 2030
Commercial significance	Combination NSCLC protection through approximately 2030

The legally operative expiration date is the term recorded in USPTO and FDA records. A patent’s grant date does not determine its expiration date. Patent-term adjustment can extend the term beyond the basic 20-year period, while terminal disclaimers can limit it.

What is the Orange Book status of US 8,952,018?

The patent is associated with the Tafinlar and Mekinist products and the dabrafenib-trametinib combination indication. FDA Orange Book listings for branded products distinguish between patents claiming:

• the active ingredient;
• a pharmaceutical composition;
• a formulation or solid form;
• a method of use; and
• a drug-product combination.

US 8,952,018 is a method-of-use patent. Its relevant use code is directed to treatment of NSCLC using the dabrafenib-trametinib combination, particularly the BRAF V600E-mutant population reflected in the approved indication.

The Orange Book consequence is material because an ANDA applicant seeking approval for a product that implicates a listed method-of-use patent may be required to submit a Paragraph IV certification, unless the applicant uses an acceptable carve-out or otherwise avoids the patented method.

Orange Book listing does not establish validity or infringement. It creates an FDA regulatory mechanism that can trigger a 30-month stay if the NDA holder or patent owner files an infringement action within the statutory period after receiving a Paragraph IV notice [3].

When did the FDA approve the dabrafenib-trametinib combination for NSCLC?

The FDA’s relevant milestones are:

FDA milestone	Date
Dabrafenib approved for BRAF-mutant melanoma	May 29, 2013
Trametinib approved for BRAF-mutant melanoma	May 29, 2013
Combination approved for BRAF-mutant melanoma	January 8, 2014
Combination approved for BRAF V600E-mutant metastatic NSCLC	May 10, 2018

The 2018 NSCLC approval was based on clinical evidence showing antitumor activity in patients with BRAF V600E-mutant metastatic NSCLC. The FDA label identifies the combination as indicated for patients with unresectable or metastatic NSCLC whose tumors have a BRAF V600E mutation, as detected by an FDA-approved test [2].

The patent predates the NSCLC approval. That timing is typical of pharmaceutical method patents: the patent protects a therapeutic use discovered during development, while the regulatory indication may be approved later.

What other patents protect Tafinlar and Mekinist?

US 8,952,018 is only one component of the broader patent estate. The surrounding portfolio can include compound, salt, formulation, manufacturing and method-of-use patents.

Patent category	Protected subject matter	Commercial effect
Dabrafenib compound patents	Chemical compound and related salts	Can delay generic dabrafenib entry
Trametinib compound patents	Chemical compound and salt forms	Can delay generic trametinib entry
Solid-form patents	Dabrafenib solvate or trametinib salt forms	Can create product-specific infringement exposure
Combination patents	Dabrafenib plus trametinib therapy	Protects combined treatment
Method-of-use patents	Melanoma, NSCLC or biomarker-defined tumors	Can restrict labeled use
Formulation patents	Capsules, tablets, excipients or release characteristics	Can limit substitution strategies
Manufacturing patents	Processes and intermediates	Can increase development and supply-chain risk

The core distinction is between product protection and use protection. A generic manufacturer may overcome an expired or invalidated compound patent but still face a listed method-of-use patent. Conversely, a manufacturer that carves out the patented use may avoid method infringement while still needing to address compound or formulation patents.

Are there Paragraph IV challenges to US 8,952,018?

A Paragraph IV challenge must be assessed against the specific product, ANDA, patent listing and litigation docket. The existence of a generic dabrafenib or trametinib development program does not establish that US 8,952,018 was challenged.

For this patent, the principal risk indicators are:

1. An ANDA seeking approval for dabrafenib or trametinib products;
2. A proposed label that includes BRAF V600E-mutant NSCLC;
3. A Paragraph IV certification against the listed combination-use patent;
4. An infringement action filed by the patent owner or NDA holder; and
5. A settlement or license permitting an agreed launch date.

A generic company can pursue several strategies:

• certify that the patent is invalid, unenforceable or not infringed;
• omit the patented NSCLC indication from its label;
• wait for patent expiration;
• negotiate a license or settlement; or
• challenge only product, formulation or compound patents.

The commercial launch date can differ substantially from the patent expiration date if a settlement grants an earlier authorized entry date. Conversely, a successful litigation outcome can block the labeled generic indication until expiration.

No specific Paragraph IV outcome should be attributed to US 8,952,018 without a confirmed ANDA notice, complaint, docket entry or settlement agreement. The patent itself does not establish that a challenge has occurred.

Which companies own or commercialize the relevant rights?

The patent-family records identify GlaxoSmithKline-related entities in the development and ownership history of dabrafenib-trametinib technology. GSK developed and commercialized Tafinlar and Mekinist before transferring its oncology business to Novartis in 2015.

Novartis became the principal commercial company for Tafinlar, Mekinist and their combination. The relevant rights can therefore involve:

• the original patent owner or applicant;
• successor entities following the GSK-Novartis transaction;
• NDA holders;
• licensees;
• authorized generic partners; and
• ANDA applicants challenging the products.

Assignments and regulatory ownership should be separated. A company may own a patent while another entity holds the NDA or commercializes the product.

How strong is the patent estate for the dabrafenib-trametinib combination?

The combination estate is commercially meaningful because it aligns with an FDA-approved biomarker-defined use and a specific marketed regimen. Its principal strengths are:

• direct coverage of dabrafenib plus trametinib;
• direct relevance to BRAF V600E-mutant NSCLC;
• coverage of the commercial drug forms;
• potential Orange Book listing;
• a term extending into approximately 2030; and
• limited practical substitutability for a generic seeking the same labeled combination indication.

Its principal limitations are:

• it does not appear to cover monotherapy;
• it is limited to NSCLC;
• the most specific claim is limited to BRAF V600E;
• the claims depend on the identity of formula I and formula II;
• infringement may depend on labeling and treatment-use evidence;
• alternative BRAF or MEK inhibitors are outside the claimed combination; and
• patent validity can be challenged on written-description, enablement, obviousness or other grounds.

The patent is stronger as an indication-blocking asset than as a barrier to manufacture of dabrafenib or trametinib generally. Its economic value is highest when a generic seeks approval with the BRAF V600E-mutant NSCLC indication intact.

What generic launch scenarios exist for Tafinlar and Mekinist?

Scenario 1: Full-label generic launch after patent expiry

A generic applicant obtains approval with the NSCLC indication and launches after all blocking patents expire or are invalidated. This is the clearest post-2030 entry scenario if the patent survives and no earlier settlement date applies.

Scenario 2: Carved-out label

The applicant omits NSCLC or the BRAF V600E-mutant NSCLC use from its label. This may reduce method-of-use exposure but can weaken the commercial value of the generic because the omitted indication may be clinically important.

Scenario 3: Authorized early entry

The applicant settles with Novartis or another rights holder and receives a license for an agreed launch date before patent expiration. The settlement may impose limits on labeling, marketing or supply.

Scenario 4: Litigation victory

The applicant prevails on invalidity or non-infringement. FDA approval and launch then depend on the remaining Orange Book patents, regulatory exclusivity and any applicable injunction.

Scenario 5: Alternative product strategy

A competitor develops a different BRAF-MEK combination, a different formulation or a product directed to a different biomarker-defined population. This may reduce direct exposure to US 8,952,018 but does not necessarily avoid separate patents covering the underlying agents or methods.

How does US 8,952,018 compare with competing BRAF-MEK patent estates?

The patent is narrower than a compound patent but more targeted than a general oncology-use patent.

Estate type	Scope	Relevance to US 8,952,018
Dabrafenib compound estate	Dabrafenib molecule, salts and manufacture	Protects the individual BRAF inhibitor
Trametinib compound estate	Trametinib molecule, salts and manufacture	Protects the individual MEK inhibitor
Dabrafenib-trametinib combination estate	Combined administration	Directly aligned with US 8,952,018
Encorafenib-binimetinib estate	Different BRAF-MEK combination	Generally outside US 8,952,018
Vemurafenib-cobimetinib estate	Different BRAF-MEK combination	Generally outside US 8,952,018
BRAF V600E diagnostic patents	Mutation testing and patient selection	May affect biomarker implementation, not the drug combination itself

US 8,952,018 does not create a platform monopoly over all BRAF-MEK combinations. It protects a defined pair of agents in a defined disease setting.

Key Takeaways

• US 8,952,018 is a method-of-treatment patent for dabrafenib plus trametinib in NSCLC.
• Formula I corresponds to dabrafenib; formula II corresponds to trametinib.
• Claim 4 is the most commercially important claim because it covers BRAF V600E-mutant NSCLC.
• Claims 2 and 3 target the commercially relevant dabrafenib solvate and trametinib methanesulfonate forms.
• The patent does not, based on the supplied claims, cover dabrafenib or trametinib monotherapy.
• The expected base expiration is approximately August 4, 2030, subject to the official USPTO term calculation.
• The patent is relevant to the FDA-approved Tafinlar-Mekinist NSCLC indication and associated Orange Book strategy.
• Generic risk depends on the proposed label, the remaining compound and formulation patents, Paragraph IV activity and any settlement license.
• The patent is an indication-specific barrier rather than a broad monopoly over all BRAF-MEK therapies.
• Novartis is the principal commercial company associated with Tafinlar and Mekinist following the transfer of GSK’s oncology business.

FAQs

Does US 8,952,018 cover dabrafenib monotherapy?

No. The supplied claims require administration of both compound I and compound II. Dabrafenib monotherapy is outside the express combination requirement.

Does US 8,952,018 cover trametinib combined with encorafenib?

No. The claims require the specific compounds represented by formula I and formula II, which correspond to dabrafenib and trametinib. A different BRAF inhibitor would generally fall outside the claimed combination.

Is BRAF V600E testing required for every claim?

No. Claim 4 expressly requires BRAF V600E-mutant NSCLC. Claims 1 and 5, as supplied, recite NSCLC without the same express mutation limitation. The scope of those broader claims would depend on claim construction and validity analysis.

Can a generic omit the NSCLC indication and still launch?

Potentially. A label carve-out may reduce infringement risk for a method-of-use patent, but it must be evaluated against the full Orange Book listing, product patents, promotional conduct and the generic’s actual proposed labeling.

Does the patent cover a single tablet containing both drugs?

Not expressly. The supplied claims require administration of both compounds but do not require a fixed-dose combination product, co-formulation or single dosage form. Separate administration of Tafinlar and Mekinist can satisfy the combination requirement if the other claim elements are met.

References

1. United States Patent and Trademark Office. (2015). U.S. Patent No. 8,952,018, Combination therapy.
2. U.S. Food and Drug Administration. (2018). FDA approves combination of dabrafenib and trametinib for metastatic non-small cell lung cancer with BRAF V600E mutation.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Novartis AG. (2015). Novartis completes acquisition of GSK oncology products.
5. U.S. Food and Drug Administration. (2024). Tafinlar (dabrafenib) and Mekinist (trametinib) prescribing information.

Drugs Protected by US Patent 8,952,018

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No					Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes					Y

International Family Members for US Patent 8,952,018

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010306653
Brazil	112012008854
Canada	2775803
Chile	2012000964
China	102655753
Colombia	6531498
Costa Rica	20120155